Cytek Biosciences (NASDAQ: CTKB) director gains 3,086 no-cost shares
Rhea-AI Filing Summary
Cytek Biosciences, Inc. (CTKB) director Glenn P. Muir reported an automatic conversion of 3,086 Restricted Stock Units into 3,086 shares of Common Stock on August 18, 2026. The RSU conversion price was $0.00 per share.
Following this transaction, Muir’s directly held RSU balance tied to this award is reported as 52,469 units, and his directly held Common Stock position from this transaction is 3,086 shares3 years in multiple tranches, including 2/36 of the total shares vesting on August 18, 2026, and additional 3/36 and 4/36 installments on specified dates thereafter, as long as the vesting conditions are met.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 3,086 shares
Net Buy
2 txns
Insider
MUIR GLENN P
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F1, F2 | 3,086 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 3,086 | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 52,469 shares (Direct);
Common Stock — 3,086 shares (Direct)
Footnotes (2)
- F1. Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- F2. The shares underlying the RSU Award shall vest over 3 years, with 2/36 of the total shares underlying the RSU Award vesting on August 18, 2026; 3/36 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; 4/36 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter; 3/36 of the total shares underlying the RSU Award vesting on May 18, 2027 and each May 18 thereafter; and 3/36 of the total shares underlying the RSU Award vesting on August 18, 2027 and each August 18 thereafter.
Key Figures
RSUs converted: 3,086 units
Common Stock acquired: 3,086 shares
Conversion price: $0.00 per share
+2 more
5 metrics
RSUs converted
3,086 units
Restricted Stock Units converted into common stock on August 18, 2026
Common Stock acquired
3,086 shares
Shares of Cytek common stock received from RSU conversion on August 18, 2026
Conversion price
$0.00 per share
Exercise or conversion price for the RSU-to-common stock transaction
RSUs following transaction
52,469 units
Total RSU balance for this award after the derivative transaction
Vesting period
3 years
Total time over which the RSU Award vests in multiple tranches
Key Terms
Restricted Stock Units, contingent right, vest, derivative security
4 terms
Restricted Stock Units financial
"Each Restricted Stock Unit (the "RSU Award") represents a contingent right"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"represents a contingent right to receive one share of the Issuer's common stock"
vest financial
"The shares underlying the RSU Award shall vest over 3 years"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
What insider transaction did CTKB director Glenn P. Muir report?
Glenn P. Muir reported the conversion of 3,086 Restricted Stock Units into 3,086 shares of Cytek Biosciences, Inc. common stock on August 18, 2026, through an M-code derivative exercise/conversion transaction.
How many Cytek Biosciences (CTKB) RSUs does Glenn P. Muir hold after this Form 4?
After the reported transaction, Glenn P. Muir holds 52,469 Restricted Stock Units related to this RSU Award, as shown by the derivative security’s total shares following the transaction.
What was the exercise or conversion price for Glenn P. Muir’s CTKB RSUs?
The Restricted Stock Units converted into Cytek Biosciences, Inc. common stock at an exercise or conversion price of $0.00 per share, meaning no cash price per share was paid in the reported transaction.
How does Glenn P. Muir’s CTKB RSU Award vest over time?
The RSU Award vests over 3 years, with 2/36 of the total shares vesting on August 18, 2026; 3/36 vesting on November 18, 2026 and each November 18 thereafter; 4/36 vesting on March 10, 2027 and each March 10 thereafter; and additional 3/36 tranches on May 18 and August 18, 2027 and annually thereafter.
Was Glenn P. Muir’s CTKB transaction under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not marked, and there is no footnote indicating the use of a Rule 10b5-1 trading plan for this transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
